2019 Press Releases

Principia

Principia Updates PRN1008 Pemphigus Clinical Program
December 31, 2019

Kitcheck logo

Kit Check’s Bluesight for Controlled Substances Solution Implemented at 10 OhioHealth Hospitals
December 16, 2019

Kitcheck logo

Omnicell and Kit Check Partner to Offer Cloud-based Solution for Tracking of Controlled Substances
December 9, 2019

Kitcheck logo

MPI Label Systems Partners With Kit Check To Provide Custom RFID Tags for Medication Inventory Tracking
December 6, 2019

Harpoon Therapeutics logo

HARPOON THERAPEUTICS AND ABBVIE ANNOUNCE LICENSING AND OPTION COLLABORATION TO ADVANCE HPN217, HARPOON’S BCMA-TARGETING TRITAC®, AND EXPAND EXISTING DISCOVERY COLLABORATION
November 21, 2019

Sierra Oncology Launches the MOMENTUM Phase 3 Clinical Trial for Patients with Myelofibrosis
November 20, 2019

ReViral

Phase 2a Study Published in Antimicrobial Agents and Chemotherapy Shows Potential of Sisunatovir (RV521) to Combat Respiratory Syncytial Virus Infection
November 18, 2019

Iterum Therapeutics Announces Completion of Enrollment in Phase 3 Clinical Trial of Oral and IV Sulopenem in Complicated Urinary Tract Infection
November 18, 2019

Aptinyx logo

Aptinyx Initiates Two Phase 2 Studies of NYX-2925 in Patients with Chronic Centralized Pain Conditions
November 12, 2019

Sierra Oncology Announces Pricing of $103 Million Public Offering of Convertible Preferred Stock and Warrants
November 7, 2019

Neurana Pharmaceuticals

Neurana Pharmaceuticals Appoints Randall Kaye, M.D., Chief Medical Officer
November 7, 2019

Arvinas logo

ARVINAS, INC. ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK
November 6, 2019

Kyruus logo

New Patient Access Survey Shows Consumers Are Increasingly Self-Empowered in Their Care Decisions and Place a Growing Premium on Convenience
November 5, 2019

Deciphera logo

Deciphera Pharmaceuticals Presents Updated Data from Ripretinib and DCC-3014 Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics News
October 29, 2019

Aptinyx logo

Aptinyx Announces Results of Phase 2 Fibromyalgia Study of NYX-2925 Have Been Selected for Late-Breaking Presentation at the American College of Rheumatology Annual Meeting
October 28, 2019

Arvinas logo

ARVINAS PRESENTS A PLATFORM UPDATE, INCLUDING INITIAL DATA FROM THE FIRST TWO CLINICAL TRIALS OF PROTAC® TARGETED PROTEIN DEGRADER
October 23, 2019

Principia

PRINCIPIA ANNOUNCES POSITIVE PRELIMINARY DATA OF PRN1008 FOR IMMUNE THROMBOCYTOPENIA IN ONGOING PHASE 1/2 TRIAL
October 15, 2019

Principia

PRINCIPIA ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK
October 15, 2019

Kyruus logo

Bozeman Health Engages Kyruus to Support its Digital Transformation and Integrate Patient Access System-wide
October 15, 2019

Principia

PRINCIPIA ANNOUNCES POSITIVE PRELIMINARY DATA OF PRN1008 FROM ITS ONGOING PHASE 2 PART B TRIAL IN PEMPHIGUS
October 10, 2019

Kyruus logo

Lafayette General Health to Elevate Consumer Digital Experience and Launch Online Scheduling with Kyruus
October 7, 2019

Kitcheck logo

Kit Check’s Agreement with Vizient Extended in Multi-Year Contract, Providing Better Visibility in Drug Diversion and Medication Tracking
October 3, 2019

Arvinas logo

ARVINAS STRENGTHENS SCIENTIFIC ADVISORY BOARD WITH LEADERS IN ONCOLOGY AND NEUROLOGICAL DISORDERS
October 2, 2019

Kyruus logo

Kyruus Named to the 2019 CB Insights Digital Health 150 List of Most Innovative Digital Health Startups
October 2, 2019

Arvinas logo

BAYER AND ARVINAS UNVEIL TARGETED PROTEIN DEGRADATION JOINT VENTURE, OERTH BIO
October 1, 2019

Deciphera logo

Deciphera Pharmaceuticals Announces Late-Breaking Oral Presentation at the ESMO 2019 Congress Demonstrating Positive Results from INVICTUS Pivotal Phase 3 Study of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors
September 30, 2019

Aptinyx logo

Three Recent Preclinical Publications Highlight NMDA Receptor Activation Facilitated by Aptinyx’s NYX-2925
September 26, 2019

Neurana Pharmaceuticals

Neurana Pharmaceuticals Announces Positive Topline Results from Phase 2 STAR Study of Tolperisone in Acute Muscle Spasms of the Back
September 23, 2019

Edgewise

Edgewise Therapeutics Closes $50 Million Series B Financing
September 17, 2019

Brightinsight logo

BrightInsight Raises Significant Capital to Enhance its Regulated Digital Health Platform and Accelerate Global Commercialization
September 5, 2019

Deciphera logo

Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
August 14, 2019

Deciphera logo

Deciphera Pharmaceuticals Reports Positive Updated Phase 1 Data for Ripretinib in Gastrointestinal Stromal Tumors
August 13, 2019

Kyruus logo

Kyruus ProviderMatch® Patient Access Platform Now Powering Patient-Provider Matching at Norton Healthcare
August 6, 2019

Neuronetics Logo

Neuronetics® Announces First TMS Patient Treated Under New Japan Reimbursement Policy
August 1, 2019

Kyruus logo

OHSU to Become First Health System in Oregon to Implement Kyruus ProviderMatch®
July 30, 2019

Arvinas logo

ARVINAS APPOINTS RONALD PECK, M.D. AS CHIEF MEDICAL OFFICER
July 29, 2019

Neuronetics Logo

Neuronetics® Launches TrakStar® Plus Patient Data Management System to Maximize Physician Time with Patients
July 29, 2019

Kitcheck logo

Kit Check Announces the Latest Bluesight for Controlled Substances Feature, Investigation Portfolios
July 1, 2019

Kitcheck logo

Kit Check and Sandoz agree to a commercialization collaboration that helps improve hospital medication administration safety
June 27, 2019

Aptinyx logo

Aptinyx Presents Preclinical Data Demonstrating Robust Activity of NYX-783 on Alcohol-Seeking Behavior and Relapse-Like Behavior in Multiple Models of Alcohol Use Disorder
June 26, 2019

Kitcheck logo

Kit Check Brings Next-Generation Medication Tracking Mainstream with FDA Pilot
June 11, 2019

Deciphera logo

Deciphera Pharmaceuticals, Inc. Expands Pipeline with Potential First-in-Class Autophagy Inhibitor to Treat Mutant RAS Cancers
June 10, 2019

Aptinyx logo

Aptinyx Reports Positive Top-line Data from Phase 2 Study of NYX-2925 in Patients with Fibromyalgia, Demonstrating Significant Effects on Both Biomarkers and Patient-Reported Pain
June 10, 2019

Neuronetics Logo

NeuroStar® Advanced Therapy Receives National Reimbursement Listing in Japan
June 3, 2019

Arvinas logo

ARVINAS RECEIVES FAST TRACK DESIGNATION FOR ITS TARGETED PROTEIN DEGRADER ARV-110 AS A TREATMENT FOR MEN WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
May 29, 2019

Principia

PRINCIPIA PRESENTS PHASE 1 DATA OF PRN1371 IN PATIENTS WITH METASTATIC BLADDER CANCER
May 20, 2019

TigerConnect

TigerConnect Names Sarah Shillington SVP of Client Success
May 15, 2019

Principia

PRINCIPIA BIOPHARMA ANNOUNCES FIRST PATIENT DOSED IN SANOFI’S PHASE 2B TRIAL OF SAR442168 IN MULTIPLE SCLEROSIS, TRIGGERING $30 MILLION MILESTONE
May 14, 2019

Aptinyx logo

Aptinyx Reports Positive Data from Phase 1 Study of Novel NMDA Receptor Modulator, NYX-458, in Healthy Volunteers
April 30, 2019

Harpoon Therapeutics logo

HARPOON THERAPEUTICS DOSES FIRST PATIENT WITH A MESOTHELIN-TARGETING T CELL ENGAGER (HPN536) IN PHASE 1/2A CLINICAL TRIAL FOR OVARIAN AND OTHER SOLID TUMOR CANCERS
April 18, 2019

Kyruus logo

Newly-Formed Prisma Health Selects Kyruus Solutions to Optimize Patient Access and Provider Network Management Post-Merger
April 17, 2019

PDS Biotechnology

PDS Biotechnology Completes Merger with Edge Therapeutics
March 18, 2019

Principia

PRINCIPIA BIOPHARMA ANNOUNCES POSITIVE DATA FROM PHASE 2 PEMPHIGUS VULGARIS TRIAL AT 2019 AMERICAN ACADEMY OF DERMATOLOGY ANNUAL MEETING IN LATE-BREAKING PRESENTATION
March 2, 2019

Harpoon Therapeutics logo

Harpoon Therapeutics Announces Pricing of Initial Public Offering
February 7, 2019

Neurana Pharmaceuticals

Neurana Pharmaceuticals Announces First Patient Enrolled in the STAR Study
February 4, 2019

Harpoon Therapeutics logo

Harpoon Therapeutics Announces Preliminary Safety and Pharmacology Data from its HPN424 Phase 1 Trial in Prostate Cancer
January 2, 2019